These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

328 related items for PubMed ID: 26531164

  • 1. Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform.
    Al-Hussaini M, Rettig MP, Ritchey JK, Karpova D, Uy GL, Eissenberg LG, Gao F, Eades WC, Bonvini E, Chichili GR, Moore PA, Johnson S, Collins L, DiPersio JF.
    Blood; 2016 Jan 07; 127(1):122-31. PubMed ID: 26531164
    [Abstract] [Full Text] [Related]

  • 2. A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates.
    Chichili GR, Huang L, Li H, Burke S, He L, Tang Q, Jin L, Gorlatov S, Ciccarone V, Chen F, Koenig S, Shannon M, Alderson R, Moore PA, Johnson S, Bonvini E.
    Sci Transl Med; 2015 May 27; 7(289):289ra82. PubMed ID: 26019218
    [Abstract] [Full Text] [Related]

  • 3. Integrated Pharmacokinetic/Pharmacodynamic Model of a Bispecific CD3xCD123 DART Molecule in Nonhuman Primates: Evaluation of Activity and Impact of Immunogenicity.
    Campagne O, Delmas A, Fouliard S, Chenel M, Chichili GR, Li H, Alderson R, Scherrmann JM, Mager DE.
    Clin Cancer Res; 2018 Jun 01; 24(11):2631-2641. PubMed ID: 29463552
    [Abstract] [Full Text] [Related]

  • 4. CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia.
    Bonifant CL, Szoor A, Torres D, Joseph N, Velasquez MP, Iwahori K, Gaikwad A, Nguyen P, Arber C, Song XT, Redell M, Gottschalk S.
    Mol Ther; 2016 Sep 29; 24(9):1615-26. PubMed ID: 27401038
    [Abstract] [Full Text] [Related]

  • 5. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia.
    Mardiros A, Dos Santos C, McDonald T, Brown CE, Wang X, Budde LE, Hoffman L, Aguilar B, Chang WC, Bretzlaff W, Chang B, Jonnalagadda M, Starr R, Ostberg JR, Jensen MC, Bhatia R, Forman SJ.
    Blood; 2013 Oct 31; 122(18):3138-48. PubMed ID: 24030378
    [Abstract] [Full Text] [Related]

  • 6. Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia.
    Tasian SK, Kenderian SS, Shen F, Ruella M, Shestova O, Kozlowski M, Li Y, Schrank-Hacker A, Morrissette JJD, Carroll M, June CH, Grupp SA, Gill S.
    Blood; 2017 Apr 27; 129(17):2395-2407. PubMed ID: 28246194
    [Abstract] [Full Text] [Related]

  • 7. Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors.
    Thokala R, Olivares S, Mi T, Maiti S, Deniger D, Huls H, Torikai H, Singh H, Champlin RE, Laskowski T, McNamara G, Cooper LJ.
    PLoS One; 2016 Apr 27; 11(8):e0159477. PubMed ID: 27548616
    [Abstract] [Full Text] [Related]

  • 8. AntiCD3Fv fused to human interleukin-3 deletion variant redirected T cells against human acute myeloid leukemic stem cells.
    Fan D, Li Z, Zhang X, Yang Y, Yuan X, Zhang X, Yang M, Zhang Y, Xiong D.
    J Hematol Oncol; 2015 Feb 28; 8():18. PubMed ID: 25879549
    [Abstract] [Full Text] [Related]

  • 9. Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma.
    Moore PA, Zhang W, Rainey GJ, Burke S, Li H, Huang L, Gorlatov S, Veri MC, Aggarwal S, Yang Y, Shah K, Jin L, Zhang S, He L, Zhang T, Ciccarone V, Koenig S, Bonvini E, Johnson S.
    Blood; 2011 Apr 28; 117(17):4542-51. PubMed ID: 21300981
    [Abstract] [Full Text] [Related]

  • 10. A Chemo-enzymatically Linked Bispecific Antibody Retargets T Cells to a Sialylated Epitope on CD43 in Acute Myeloid Leukemia.
    Bartels L, de Jong G, Gillissen MA, Yasuda E, Kattler V, Bru C, Fatmawati C, van Hal-van Veen SE, Cercel MG, Moiset G, Bakker AQ, van Helden PM, Villaudy J, Hazenberg MD, Spits H, Wagner K.
    Cancer Res; 2019 Jul 01; 79(13):3372-3382. PubMed ID: 31064847
    [Abstract] [Full Text] [Related]

  • 11. [Preparation of a dual-specific antibody targeting human CD123 and exploration of its anti-acute myeloid leukemia effects].
    Zhou T, Chen ML, Zhang CY, Liu XY, Wang ZZ, Xing HY, Tang KJ, Tian Z, Rao Q, Wang M, Wang JX.
    Zhonghua Xue Ye Xue Za Zhi; 2024 Mar 14; 45(3):225-232. PubMed ID: 38716593
    [Abstract] [Full Text] [Related]

  • 12. The CD33xCD123xCD70 Multispecific CD3-Engaging DARPin MP0533 Induces Selective T Cell-Mediated Killing of AML Leukemic Stem Cells.
    Bianchi M, Reichen C, Croset A, Fischer S, Eggenschwiler A, Grübler Y, Marpakwar R, Looser T, Spitzli P, Herzog C, Villemagne D, Schiegg D, Abduli L, Iss C, Neculcea A, Franchini M, Lekishvili T, Ragusa S, Zitt C, Kaufmann Y, Auge A, Hänggi M, Ali W, Frasconi TM, Wullschleger S, Schlegel I, Matzner M, Lüthi U, Schlereth B, Dawson KM, Kirkin V, Ochsenbein AF, Grimm S, Reschke N, Riether C, Steiner D, Leupin N, Goubier A.
    Cancer Immunol Res; 2024 Jul 02; 12(7):921-943. PubMed ID: 38683145
    [Abstract] [Full Text] [Related]

  • 13. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells.
    Gill S, Tasian SK, Ruella M, Shestova O, Li Y, Porter DL, Carroll M, Danet-Desnoyers G, Scholler J, Grupp SA, June CH, Kalos M.
    Blood; 2014 Apr 10; 123(15):2343-54. PubMed ID: 24596416
    [Abstract] [Full Text] [Related]

  • 14. Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment.
    Bonnevaux H, Guerif S, Albrecht J, Jouannot E, De Gallier T, Beil C, Lange C, Leuschner WD, Schneider M, Lemoine C, Caron A, Amara C, Barrière C, Siavellis J, Bardet V, Luna E, Agrawal P, Drake DR, Rao E, Wonerow P, Carrez C, Blanc V, Hsu K, Wiederschain D, Fraenkel PG, Virone-Oddos A.
    Oncoimmunology; 2021 Apr 10; 10(1):1945803. PubMed ID: 34484869
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Selective recruitment of γδ T cells by a bispecific antibody for the treatment of acute myeloid leukemia.
    Ganesan R, Chennupati V, Ramachandran B, Hansen MR, Singh S, Grewal IS.
    Leukemia; 2021 Aug 10; 35(8):2274-2284. PubMed ID: 33526858
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A novel bispecific T-cell engager using the ligand-target csGRP78 against acute myeloid leukemia.
    Zeng X, Zhang H, Guo J, Yang D, Zhu Y, Liu N, Tang J, Liu T, Zhao X.
    Cell Mol Life Sci; 2024 Aug 28; 81(1):371. PubMed ID: 39196413
    [Abstract] [Full Text] [Related]

  • 20. Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC.
    Busfield SJ, Biondo M, Wong M, Ramshaw HS, Lee EM, Ghosh S, Braley H, Panousis C, Roberts AW, He SZ, Thomas D, Fabri L, Vairo G, Lock RB, Lopez AF, Nash AD.
    Leukemia; 2014 Nov 28; 28(11):2213-21. PubMed ID: 24705479
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.